Hormone-receptor positive (HR+) breast cancer accounts for between 60-80% of all breast cancer cases, with the HR+/HER2- subtype having been identified as the most predominant in Western countries.Approximately 30% of individuals diagnosed with HR+ breast cancer will eventually experience relapse with metastatic disease. Endocrine therapy targeting the estrogen receptor has historically been a fundamental component of treatment in the metastatic setting. First-line treatment previously recommended for post-menopausal women with HR+/HER2- metastatic breast cancer included either aromatase inhibitors or selective estrogen receptor degraders. Resistance to endocrine therapy in women with HR+ metastatic disease frequently occurs, however, with a number of different mechanisms being implicated. This has prompted the need for newer treatment options.
Fellows of The Royal Australasian College of Physicians (RACP) can claim CPD credits in MyCPD for participation in this course. www.racp.edu.au/mycpd (log in to MyCPD). The program has been reviewed and approved by the Clinical Oncology Society of Australia.
Professor Frances Boyle
MBBS, PhD, FRACP, GAICD
Professor of Medical Oncology, University of Sydney
Medical Oncologist, Mater Hospital, North Sydney, NSW
Richard de Boer
Consultant Medical Oncologist,
Peter MacCallum Cancer Centre, Melbourne, VIC
On completion of this program, oncologists will be better able to
- Evaluate the efficacy and safety of ribociclib (Kisqali®) in the treatment of patients with hormone receptor positive (HR+), HER2-negative (HER2-) metastatic breast cancer
- Identify the role of ribociclib in the treatment of post-menopausal women with HR+/HER2- breast cancer
- Recognise the benefits of a multi-disciplinary team approach when treating a patient with HR+/HER2– advanced or metastatic breast cancer